Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure.
Felker
G M
GM
O'connor
C M
CM
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000191:economics; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002316:Cardiotonic Agents / Q000009:adverse effects* / Q000191:economics; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D006333:Heart Failure / Q000188:drug therapy*; D016027:Heart Transplantation; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D012107:Research Design; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D002316:Cardiotonic Agents